



Clearbridge expands range of medical services with acquisition of a medical clinic in Singapore

- *Completes acquisition of an 85% stake in medical aesthetics clinic for S\$5.5 million*
 - *Acquisition is expected to lead to revenue and cost synergies*

SINGAPORE – 2 April 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited with a focus on the delivery of precision medicine in Asia, has completed the acquisition of a 85% stake in Medic Surgical Private Limited (“MSPL”) and Medic Laser Private Limited (“MLPL”). MSPL and MLPL collectively operate a clinic under the name “Medic Surgery and Laser Clinic” (“MSLC”) in Tanjong Pagar.

Out of the aggregate consideration of S\$5.5 million, S\$2.0 million will be paid in cash and S\$3.5 million will be satisfied by the issuance of 6,337,136 new ordinary shares in the capital of Clearbridge. This is in line with the Group’s commitment to optimise its capital structure to enhance shareholder value while expanding its businesses in a sustainable and prudent manner.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said: *“The acquisition of MSLC will allow us to tap on the strong and growing demand for medical and aesthetics services in Singapore, and is in line with Clearbridge’s growth strategy to acquire profitable and cash generating businesses. The acquisition also provides the Group with an additional pillar of growth as we continue to expand our presence in Singapore and overseas. Moreover, we expect the acquisition to generate significant cost synergies and economies of scale as we will be able to deploy other wellness products and laboratory testing services within the Group through the expanded network of clinics in Singapore especially in the area of medical aesthetics.”*

MSLC is located on the outskirts of Singapore’s bustling central business district and caters mainly to working professionals seeking general medicine services and high-end dermatology treatments at affordable prices. The acquisition will allow Clearbridge to distribute its suite of precision medicine products and services to benefit from revenue synergies within the Group.

With the addition of MSLC, Clearbridge has doubled its network of medical centres/clinics over the last three months across the region and it now owns and operates two medical centres/clinics in Singapore and one medical centre/clinic each in Hong Kong and the Philippines.

-- END --

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and



strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at www.clearbridgehealth.com.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.